REM Sleep Behavior Disorder

Neurological Disorder MONDO:0005937 Pathograph 9 Show in embeddings browser Sleep Disorder Neurological Disease

REM sleep behavior disorder is a parasomnia in which the skeletal muscle atonia that normally accompanies REM sleep fails, so that the motor programmes generated during dreaming are executed rather than suppressed. Patients punch, kick, shout, and leap from bed, frequently injuring themselves or a bed partner, and wake alert with matching dream recall. Diagnosis requires both the behavioural history and polysomnographic demonstration of REM sleep without atonia. What makes the disorder important beyond its immediate injury risk is what it signifies: in older adults the isolated (idiopathic) form is not idiopathic at all but the earliest clinically detectable stage of an alpha-synuclein neurodegenerative disease. Post-mortem series find Lewy body disease in the overwhelming majority, with alpha-synuclein deposited in precisely the brainstem structures that regulate REM atonia, and prospective follow-up shows conversion to Parkinson disease, dementia with Lewy bodies, or multiple system atrophy at about 6% per year, reaching roughly three-quarters by twelve years. That combination - a specific, polysomnographically verifiable marker with a decade-long lead time over an overt neurodegenerative syndrome - makes it the most powerful prodromal state available in neurodegeneration, and the population in which disease-modifying trials are most feasible.

Ask OpenScientist

Ask a research question about REM Sleep Behavior Disorder. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

6
Pathophys.
3
Phenotypes
2
Gaps
9
Pathograph
3
Medical Actions
🏷

Classifications

Harrison's Part
NEUROLOGIC
?

Discussions and Knowledge Gaps

2
Can the decade-long prodromal window in this disorder be used to demonstrate neuroprotection, and what endpoint would show it?
KNOWLEDGE GAP gap_neuroprotection_trial_window
This entry describes the most favourable setting neurodegeneration offers for a disease-modifying trial: an objectively verifiable marker, a defined at-risk population, a conversion rate high enough to power a trial (142-366 patients per arm on published estimates), and roughly a decade of lead time before overt disease. Nothing has been shown to alter that trajectory, and the obstacle is partly an endpoint problem. Phenoconversion is a clinical diagnosis made years downstream and is a coarse, late outcome; the entry's own central node (quantified atonia loss) is closer to the pathology but its relationship to progression elsewhere in the brain is itself unresolved. Whether a shorter-term biological endpoint can substitute determines whether trials in this population are feasible at all.
Proposed experiments
Validation of short-term progression markers against phenoconversion
exp_rbd_surrogate_endpoint_validation
In an existing multicentre isolated-REM-sleep-behavior-disorder cohort with long follow-up, test candidate short-horizon markers - seed-amplification assay alpha-synuclein status, serial dopamine-transporter imaging, quantitative atonia loss, olfactory and autonomic measures - against observed phenoconversion, to establish whether any change over two to three years predicts the clinical endpoint well enough to serve as a trial outcome.
Does isolated REM sleep without atonia, nine times commoner than the full disorder, carry the same prodromal meaning?
KNOWLEDGE GAP gap_isolated_rwa_natural_history
Population screening finds isolated REM sleep without atonia in 12.5% of adults aged 50-80, against 1.4% with the full disorder. If that finding carried the same phenoconversion risk, it would imply a prodromal synucleinopathy population an order of magnitude larger than currently recognised - which is either a major public-health observation or evidence that the polysomnographic marker is far less specific than its use as a mandatory criterion assumes. The entry curates the two as separable for that reason, and the question is directly answerable by follow-up rather than requiring new methods.
Proposed experiments
Prospective follow-up of population-ascertained isolated atonia loss
exp_isolated_rwa_prospective_followup
Long-term prospective surveillance of population-screened individuals with isolated REM sleep without atonia, isolated dream enactment, and neither, with incident parkinsonism and dementia as outcomes, to establish whether the polysomnographic marker alone confers the risk attached to the full syndrome.

Pathophysiology

6
Alpha-Synuclein Pathology in the Brainstem REM-Atonia Circuit
The trigger in the common, age-related form. Alpha-synuclein aggregates and associated neuronal loss and gliosis involve the pontomedullary structures that generate REM atonia - the subcoeruleus nucleus (the human homologue of the rodent sublaterodorsal nucleus), the gigantocellular reticular nucleus, and the laterodorsal tegmentum - at a stage when nigrostriatal and cortical structures are still relatively spared. The anatomical specificity is the point: this is not incidental pathology in a diffusely affected brain but involvement of the exact circuit whose failure the syndrome expresses, which is what licenses reading the parasomnia as a topographically early stage of the disease rather than as an associated feature. Alternative triggers substitute at this node: a structural pontine lesion, the state instability of narcolepsy type 1, or serotonergic/noradrenergic antidepressant exposure.
neuron of the subcoeruleus and pontomedullary REM-atonia circuit CL:0000540 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves decreased neuron of the subcoeruleus and pontomedullary REM-atonia circuit, annotated with neuron (CL:0000540). CL:0000540 is a cell type from the Cell Ontology. ↓ DECREASED
pons UBERON:0000988 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in pons (UBERON:0000988). UBERON:0000988 is an anatomical location from the Uberon multi-species anatomy ontology. brainstem UBERON:0002298 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brainstem (UBERON:0002298). UBERON:0002298 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (3 references)
PMID:39577924 SUPPORT Human Clinical
"In all participants, α-synuclein was found in the structures that regulate REM sleep atonia (eg, subcoeruleus nucleus, gigantocellular reticular nucleus, laterodorsal tegmentum, and amygdala)."
Direct post-mortem demonstration, in every case examined, that the pathology sits in the specific atonia-regulating structures - the anatomical specificity this node asserts.
PMID:39577924 SUPPORT Human Clinical
"Post-mortem neuropathological diagnoses were Lewy body disease in 19 (95%) and multiple system atrophy (MSA) in one (5%)."
Establishes that the underlying pathology is a synucleinopathy in essentially all cases coming to autopsy, which is the basis for curating the degenerative aetiology as the principal trigger.
PMID:17412731 SUPPORT Human Clinical
"Neuroimaging data from the few published human cases with RBD associated with structural lesions in the brainstem are presented, in which the dorsal midbrain and pons are implicated."
The lesional substitution at this node - a discrete structural lesion at the same site reproduces the syndrome, which is what makes the location rather than the pathology the causal factor.
Loss of Descending Drive to Inhibitory Premotor Neurons
REM atonia is actively imposed rather than passively permitted: glutamatergic REM-on neurons excite glycinergic and GABAergic premotor neurons in the ventromedial medulla and spinal cord, which hyperpolarise skeletal motor neurons. Losing the descending drive releases motor neurons from an inhibition that should be present. The critical anatomical fact is that this descending pathway is separate from the ascending pathway generating the EEG features of REM sleep - so atonia can be lost while REM sleep itself proceeds entirely normally, which is exactly what polysomnography shows in these patients.
glutamatergic synaptic transmission GO:0035249 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased glutamatergic synaptic transmission, annotated with synaptic transmission, glutamatergic (GO:0035249). GO:0035249 is a biological process from the Gene Ontology. ↓ DECREASED
brainstem UBERON:0002298 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in brainstem (UBERON:0002298). UBERON:0002298 is an anatomical location from the Uberon multi-species anatomy ontology.
Show evidence (2 references)
PMID:17884926 SUPPORT Model Organism
"In the REM-on area are two populations of glutamatergic neurons, the first of which projects to the basal forebrain and regulates EEG components of REM sleep and the second of which projects to the ventromedial medulla and spinal cord and regulates atonia during REM sleep."
Establishes the two-population anatomy on which this node and the dissociation below it depend.
PMID:17884926 SUPPORT Model Organism
"Our findings demonstrating independent pathways mediating atonia and the EEG components of REM provide a basis for their occasional dissociation in pathological states, e.g. REM sleep behaviour disorder."
Names this disorder as the pathological instance of the dissociation, which is the mechanistic claim of the entry.
REM Sleep Without Atonia
The central, measurable abnormality: excess tonic or phasic electromyographic activity scored during REM sleep. It is graded rather than binary, and its magnitude carries prognostic weight - quantified atonia loss is among the significant predictors of phenoconversion. It is also separable from the clinical behaviours: population screening finds isolated REM sleep without atonia roughly nine times more often than full disorder, which suggests it is the earlier and more sensitive marker of the same process, though whether every case progresses is unknown.
REM sleep GO:0042747 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal REM sleep, annotated with circadian sleep/wake cycle, REM sleep (GO:0042747). GO:0042747 is a biological process from the Gene Ontology. ⚠ ABNORMAL skeletal muscle contraction during REM sleep GO:0003009 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased skeletal muscle contraction during REM sleep, annotated with skeletal muscle contraction (GO:0003009). GO:0003009 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (2 references)
PMID:30166532 SUPPORT Other
"A clinical history of dream enactment or complex motor behaviours together with the presence of muscle activity during REM sleep confirmed by video polysomnography are mandatory for a definite RBD diagnosis."
Establishes the measurement standard for this node and that it is mandatory rather than supportive.
PMID:37816644 SUPPORT Human Clinical
"Sex and DEB frequency-adjusted prevalence of RBD was 1.4% (95% CI 1.0%-1.8%), isolated RWA was 12.5% (95% CI 11.3%-13.6%), and isolated DEB was 3.4% (95% CI 2.7%-4.1%)."
Quantifies the dissociation this node describes: isolated REM sleep without atonia is roughly nine times commoner in the population than the full disorder.
Dream Enactment Behaviour
Released motor output takes the form of behaviour matched to dream content - the observation that ties the syndrome to REM physiology rather than to a nonspecific motor release. Because dream content in this population is disproportionately confrontational, the behaviours are frequently violent, and injury to the patient or bed partner is the presenting problem. Unlike an NREM parasomnia the episodes are not preceded by confusional arousal, and the patient wakes alert with dream recall that matches the observed behaviour.
muscle contraction GO:0006936 Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves increased muscle contraction (GO:0006936). GO:0006936 is a biological process from the Gene Ontology. ↑ INCREASED
Show evidence (1 reference)
PMID:17412731 SUPPORT Other
"REM sleep behaviour disorder (RBD) is a parasomnia characterized by the loss of normal skeletal muscle atonia during REM sleep with prominent motor activity accompanying dreaming."
Links the released motor activity specifically to dreaming, which is what distinguishes this node from a generic nocturnal motor phenomenon.
Progression to Overt Synucleinopathy
The second consequence, of a different kind and applying only to the degenerative route. The brainstem pathology spreads to involve nigral and limbic-cortical structures, and the patient converts to Parkinson disease, dementia with Lewy bodies, or multiple system atrophy. Conversion runs at about 6.3% per year, reaching 73.5% by twelve years - high, but neither immediate nor universal, and the distinction matters when counselling. The post-mortem series adds a topographic dimension worth preserving: those who remained free of another neurological disorder, or who developed Parkinson disease without dementia, had alpha-synuclein largely confined to brainstem and limbic system with few coexisting pathologies, whereas those who developed dementia had diffuse cortical involvement and frequent comorbid Alzheimer pathology - so the destination, not just the timing, tracks the extent of spread.
Show evidence (3 references)
PMID:30789229 SUPPORT Human Clinical
"The overall conversion rate from iRBD to an overt neurodegenerative syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up."
Quantifies the conversion risk in a 1280-patient multicentre cohort, which is what allows this node to state a rate rather than an association.
PMID:39577924 SUPPORT Human Clinical
"In individuals with IRBD without any other neurological disorder and in those who developed Parkinson's disease without dementia, α-synuclein was found in the brainstem and limbic system and rarely in the cortex, whereas coexisting proteinopathies were few and showed mild pathological burden."
Supports the topographic claim in the node description - that the clinical destination tracks the anatomical extent of spread, not merely its duration.
PMID:39577924 SUPPORT Human Clinical
"Concomitant pathologies are frequent and their role remains to be clarified: some might have contributed to the development of dementia, but some might be age-related changes."
Cited as PARTIAL because it withholds the causal reading of the comorbid pathologies rather than supporting it - the association with dementia is observed, its causal contribution explicitly not established.

Pathograph

Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for REM Sleep Behavior Disorder Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.

Phenotypes

3
Nervous System 2
Dream Enactment Behaviour OBLIGATE REM sleep behavior disorder HP:5200291 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is REM sleep behavior disorder (HP:5200291), qualified as temporality recurrent. HP:5200291 is a phenotype from the Human Phenotype Ontology.
Temporal: RECURRENT
Show evidence (1 reference)
PMID:30166532 SUPPORT Other
"abnormal behaviours occurring during REM sleep, often as dream enactments that can cause injury"
OBLIGATE by definition rather than by observation: dream enactment history is a mandatory diagnostic criterion, so every diagnosed patient has it.
REM Sleep Without Atonia OBLIGATE Abnormal rapid eye movement sleep HP:0002494 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Abnormal rapid eye movement sleep (HP:0002494). HP:0002494 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:30166532 SUPPORT Other
"characterized by loss of muscle atonia during REM sleep (known as REM sleep without atonia, or RSWA)"
OBLIGATE by definition: polysomnographic REM sleep without atonia is a mandatory criterion for definite diagnosis.
Other 1
💊

Medical Actions

3
Sleep Environment Safety Measures
Action: Supportive CareNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Supportive Care (NCIT:C15747). NCIT:C15747 is a clinical intervention from the NCI Thesaurus. NCIT:C15747
Removal of bedside weapons and injury-capable objects, padding of sharp furniture and headboard, soft floor covering beside the bed, and separate sleeping arrangements in severe uncontrolled cases. Graded as a good-practice statement whose implementation is necessary for appropriate management - that is, ahead of any pharmacological recommendation in the guideline's own ordering. It addresses the injury consequence directly and has no mechanistic action, which is precisely why it is the most reliably effective intervention available.
Mechanism Target:
INHIBITS Sleep-Related Injury — Removes the physical means of injury without altering the released motor behaviour, acting on the consequence rather than on any upstream node.
Show evidence (1 reference)
PMID:36515157 SUPPORT Human Clinical
"The following good practice statement is based on expert consensus, and its implementation is necessary for the appropriate and effective management of patients with RBD"
Records both the recommendation and its evidence basis (expert consensus), and its placement ahead of the graded drug recommendations.
Clonazepam
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: clonazepam CHEBI:3756 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses clonazepam (CHEBI:3756). CHEBI:3756 is a therapeutic agent from Chemical Entities of Biological Interest.
Low-dose benzodiazepine that suppresses the enacted behaviours. It acts on the behavioural effector node and is not disease-modifying; the AASM recommendation is conditional. Sedation, falls and cognitive effects are material concerns in a population that is by definition in a neurodegenerative prodrome.
Mechanism Target:
INHIBITS Dream Enactment Behaviour — Suppresses released motor behaviour without restoring REM atonia or altering the underlying pathology.
Show evidence (1 reference)
PMID:36515157 SUPPORT Human Clinical
"The AASM suggests that clinicians use clonazepam (vs no treatment) for the treatment of isolated RBD in adults. (CONDITIONAL)."
Cited as PARTIAL because the guideline's own strength assignment is conditional rather than strong.
Immediate-Release Melatonin
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: melatonin CHEBI:16796 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses melatonin (CHEBI:16796). CHEBI:16796 is a therapeutic agent from Chemical Entities of Biological Interest.
The alternative symptomatic agent, generally preferred where sedation, falls, or cognitive impairment make a benzodiazepine unattractive. Also a conditional recommendation, and also acting on the behavioural node rather than on the pathology.
Mechanism Target:
INHIBITS Dream Enactment Behaviour — Reduces frequency and intensity of enacted behaviours; not shown to restore REM atonia or to alter progression.
Show evidence (1 reference)
PMID:36515157 SUPPORT Human Clinical
"The AASM suggests that clinicians use immediate-release melatonin (vs no treatment) for the treatment of isolated RBD in adults. (CONDITIONAL)."
Cited as PARTIAL for the same reason as clonazepam: a conditional recommendation, so neither agent may be curated as established therapy.
🔬

Diagnosis

1
Video polysomnography with quantified REM atonia scoring
The mandatory diagnostic test, and the only one that establishes the entity. Submental (with or without limb) electromyographic activity is scored during REM sleep, and simultaneous video captures the behaviours. "Any" EMG activity at a threshold around 22% performs best against clinical diagnosis in population screening. Screening questionnaires are not adequate substitutes: a positive RBD screening questionnaire had good specificity but a positive predictive value under 8% in the general population, meaning over twelve in thirteen screen-positive people do not have the disorder.
Show evidence (2 references)
PMID:37816644 SUPPORT Human Clinical
"Among the RWA parameters, any EMG activity showed the best association with the RBD and its possible prodromes (area under the curve, 0.917)."
Identifies the best-performing polysomnographic parameter for this diagnosis.
PMID:37816644 REFUTE Human Clinical
"RBDSQ score of ≥5 had good specificity but poor positive predictive value (PPV) for RBD (specificity 84.1% and PPV 7.7%)"
Cited as REFUTE against the use of questionnaire screening as a substitute for polysomnography at population level, which is the practical point this diagnostic entry makes.
📊

Prevalence

1
Korean population-based cohort aged 50-80, home polysomnography confirmed
Point Prevalence 1400.0 per 100,000 (1000.0–1800.0) >1 in 1,000
Polysomnography-confirmed prevalence in adults aged 50-80. Consistent with other recent population-based estimates of 1.18-1.34%. Isolated REM sleep without atonia, the presumed prodrome, was roughly nine times commoner at 12.5%.
Show evidence (2 references)
PMID:37816644 SUPPORT Human Clinical
"Sex and DEB frequency-adjusted prevalence of RBD was 1.4% (95% CI 1.0%-1.8%), isolated RWA was 12.5% (95% CI 11.3%-13.6%)"
Gives the adjusted point prevalence and confidence interval directly, and the prodromal-state figure quoted in the note.
PMID:37816644 SUPPORT Human Clinical
"The prevalence of polysomnography (PSG)–confirmed RBD is suggested at 1.18%–1.34%, based on recent population-based studies."
Corroborates the estimate against other population-based series, which is what the note refers to.
{ }

Source YAML

click to show
name: REM Sleep Behavior Disorder
creation_date: "2026-08-24T00:00:00Z"
category: Neurological Disorder
parents:
- Sleep Disorder
- Neurological Disease
disease_term:
  preferred_term: REM sleep behavior disorder
  term:
    id: MONDO:0005937
    label: REM sleep behavior disorder
description: >-
  REM sleep behavior disorder is a parasomnia in which the skeletal muscle
  atonia that normally accompanies REM sleep fails, so that the motor programmes
  generated during dreaming are executed rather than suppressed. Patients punch,
  kick, shout, and leap from bed, frequently injuring themselves or a bed
  partner, and wake alert with matching dream recall. Diagnosis requires both
  the behavioural history and polysomnographic demonstration of REM sleep
  without atonia. What makes the disorder important beyond its immediate injury
  risk is what it signifies: in older adults the isolated (idiopathic) form is
  not idiopathic at all but the earliest clinically detectable stage of an
  alpha-synuclein neurodegenerative disease. Post-mortem series find Lewy body
  disease in the overwhelming majority, with alpha-synuclein deposited in
  precisely the brainstem structures that regulate REM atonia, and prospective
  follow-up shows conversion to Parkinson disease, dementia with Lewy bodies, or
  multiple system atrophy at about 6% per year, reaching roughly three-quarters
  by twelve years. That combination - a specific, polysomnographically
  verifiable marker with a decade-long lead time over an overt neurodegenerative
  syndrome - makes it the most powerful prodromal state available in
  neurodegeneration, and the population in which disease-modifying trials are
  most feasible.
notes: >-
  SCOPE. This entry covers REM sleep behavior disorder as an entity, spanning
  the isolated form and the symptomatic forms (antidepressant-associated,
  narcolepsy type 1-associated, and that occurring in established
  synucleinopathy). The isolated form's prodromal significance is curated as a
  consequence of the degenerative aetiology, not of the syndrome, so the
  antidepressant-associated presentation does not inherit it - see the module's
  open discussion on whether the two routes are genuinely separable.

  DIFFERENTIAL DISCIPLINE. Nocturnal motor behaviour is not this disorder. NREM
  parasomnias arise from incomplete arousal out of slow-wave sleep, typically in
  the first third of the night, with confusion and no dream recall; sleep-related
  hypermotor (nocturnal frontal lobe) epilepsy produces stereotyped, brief,
  clustered events. Both occur with an entirely intact REM-atonia circuit. This
  is why the polysomnographic criterion is not a formality: without it the
  entity dissolves into "things people do at night".
pathophysiology:
- name: Alpha-Synuclein Pathology in the Brainstem REM-Atonia Circuit
  description: >-
    The trigger in the common, age-related form. Alpha-synuclein aggregates and
    associated neuronal loss and gliosis involve the pontomedullary structures
    that generate REM atonia - the subcoeruleus nucleus (the human homologue of
    the rodent sublaterodorsal nucleus), the gigantocellular reticular nucleus,
    and the laterodorsal tegmentum - at a stage when nigrostriatal and cortical
    structures are still relatively spared. The anatomical specificity is the
    point: this is not incidental pathology in a diffusely affected brain but
    involvement of the exact circuit whose failure the syndrome expresses, which
    is what licenses reading the parasomnia as a topographically early stage of
    the disease rather than as an associated feature. Alternative triggers
    substitute at this node: a structural pontine lesion, the state instability
    of narcolepsy type 1, or serotonergic/noradrenergic antidepressant exposure.
  role: trigger
  biological_scale: CELLULAR
  conforms_to: "rem_sleep_atonia_control_failure#Lesion of the Pontine REM-Atonia Generator"
  cell_types:
  - preferred_term: neuron of the subcoeruleus and pontomedullary REM-atonia circuit
    term:
      id: CL:0000540
      label: neuron
    modifier: DECREASED
  locations:
  - preferred_term: pons
    term:
      id: UBERON:0000988
      label: pons
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  evidence:
  - reference: PMID:39577924
    reference_title: "Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In all participants, α-synuclein was found in the structures that regulate
      REM sleep atonia (eg, subcoeruleus nucleus, gigantocellular reticular
      nucleus, laterodorsal tegmentum, and amygdala).
    explanation: >-
      Direct post-mortem demonstration, in every case examined, that the
      pathology sits in the specific atonia-regulating structures - the
      anatomical specificity this node asserts.
  - reference: PMID:39577924
    reference_title: "Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Post-mortem neuropathological diagnoses were Lewy body disease in 19 (95%)
      and multiple system atrophy (MSA) in one (5%).
    explanation: >-
      Establishes that the underlying pathology is a synucleinopathy in
      essentially all cases coming to autopsy, which is the basis for curating
      the degenerative aetiology as the principal trigger.
  - reference: PMID:17412731
    reference_title: Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease.
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Neuroimaging data from the few published human cases with RBD associated
      with structural lesions in the brainstem are presented, in which the dorsal
      midbrain and pons are implicated.
    explanation: >-
      The lesional substitution at this node - a discrete structural lesion at
      the same site reproduces the syndrome, which is what makes the location
      rather than the pathology the causal factor.
  downstream:
  - target: Loss of Descending Drive to Inhibitory Premotor Neurons
    description: >-
      Loss of the REM-on population removes the excitatory drive its descending
      axons carry to medullary and spinal inhibitory premotor neurons.
    causal_link_type: DIRECT

- name: Loss of Descending Drive to Inhibitory Premotor Neurons
  description: >-
    REM atonia is actively imposed rather than passively permitted: glutamatergic
    REM-on neurons excite glycinergic and GABAergic premotor neurons in the
    ventromedial medulla and spinal cord, which hyperpolarise skeletal motor
    neurons. Losing the descending drive releases motor neurons from an inhibition
    that should be present. The critical anatomical fact is that this descending
    pathway is separate from the ascending pathway generating the EEG features of
    REM sleep - so atonia can be lost while REM sleep itself proceeds entirely
    normally, which is exactly what polysomnography shows in these patients.
  role: amplifier
  biological_scale: CELLULAR
  conforms_to: "rem_sleep_atonia_control_failure#Loss of Descending Glutamatergic Drive to Inhibitory Premotor Neurons"
  biological_processes:
  - preferred_term: glutamatergic synaptic transmission
    term:
      id: GO:0035249
      label: synaptic transmission, glutamatergic
    modifier: DECREASED
  locations:
  - preferred_term: brainstem
    term:
      id: UBERON:0002298
      label: brainstem
  evidence:
  - reference: PMID:17884926
    reference_title: "The pontine REM switch: past and present."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      In the REM-on area are two populations of glutamatergic neurons, the first
      of which projects to the basal forebrain and regulates EEG components of
      REM sleep and the second of which projects to the ventromedial medulla and
      spinal cord and regulates atonia during REM sleep.
    explanation: >-
      Establishes the two-population anatomy on which this node and the
      dissociation below it depend.
  - reference: PMID:17884926
    reference_title: "The pontine REM switch: past and present."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: >-
      Our findings demonstrating independent pathways mediating atonia and the
      EEG components of REM provide a basis for their occasional dissociation in
      pathological states, e.g. REM sleep behaviour disorder.
    explanation: >-
      Names this disorder as the pathological instance of the dissociation,
      which is the mechanistic claim of the entry.
  downstream:
  - target: REM Sleep Without Atonia
    description: >-
      Without descending excitation of the inhibitory premotor pool, skeletal
      motor neurons are not hyperpolarised during REM sleep and muscle tone
      persists.
    causal_link_type: DIRECT

- name: REM Sleep Without Atonia
  description: >-
    The central, measurable abnormality: excess tonic or phasic electromyographic
    activity scored during REM sleep. It is graded rather than binary, and its
    magnitude carries prognostic weight - quantified atonia loss is among the
    significant predictors of phenoconversion. It is also separable from the
    clinical behaviours: population screening finds isolated REM sleep without
    atonia roughly nine times more often than full disorder, which suggests it is
    the earlier and more sensitive marker of the same process, though whether
    every case progresses is unknown.
  role: central_effector
  biological_scale: ORGANISM
  conforms_to: "rem_sleep_atonia_control_failure#Failure of REM Sleep Skeletal Muscle Atonia"
  biological_processes:
  - preferred_term: REM sleep
    term:
      id: GO:0042747
      label: circadian sleep/wake cycle, REM sleep
    modifier: ABNORMAL
  - preferred_term: skeletal muscle contraction during REM sleep
    term:
      id: GO:0003009
      label: skeletal muscle contraction
    modifier: INCREASED
  evidence:
  - reference: PMID:30166532
    reference_title: REM sleep behaviour disorder.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      A clinical history of dream enactment or complex motor behaviours together
      with the presence of muscle activity during REM sleep confirmed by video
      polysomnography are mandatory for a definite RBD diagnosis.
    explanation: >-
      Establishes the measurement standard for this node and that it is
      mandatory rather than supportive.
  - reference: PMID:37816644
    reference_title: "REM Sleep Behavior Disorder and Its Possible Prodromes in General Population: Prevalence, Polysomnography Findings, and Associated Factors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sex and DEB frequency-adjusted prevalence of RBD was 1.4% (95% CI
      1.0%-1.8%), isolated RWA was 12.5% (95% CI 11.3%-13.6%), and isolated DEB
      was 3.4% (95% CI 2.7%-4.1%).
    explanation: >-
      Quantifies the dissociation this node describes: isolated REM sleep
      without atonia is roughly nine times commoner in the population than the
      full disorder.
  downstream:
  - target: Dream Enactment Behaviour
    description: >-
      With motor neurons no longer inhibited, the motor programmes generated
      during REM dreaming are executed.
    causal_link_type: DIRECT

- name: Dream Enactment Behaviour
  description: >-
    Released motor output takes the form of behaviour matched to dream content -
    the observation that ties the syndrome to REM physiology rather than to a
    nonspecific motor release. Because dream content in this population is
    disproportionately confrontational, the behaviours are frequently violent,
    and injury to the patient or bed partner is the presenting problem. Unlike an
    NREM parasomnia the episodes are not preceded by confusional arousal, and the
    patient wakes alert with dream recall that matches the observed behaviour.
  role: effector
  biological_scale: ORGANISM
  conforms_to: "rem_sleep_atonia_control_failure#Motor Enactment of Dream Content During REM Sleep"
  biological_processes:
  - preferred_term: muscle contraction
    term:
      id: GO:0006936
      label: muscle contraction
    modifier: INCREASED
  evidence:
  - reference: PMID:17412731
    reference_title: Pathophysiology of REM sleep behaviour disorder and relevance to neurodegenerative disease.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      REM sleep behaviour disorder (RBD) is a parasomnia characterized by the
      loss of normal skeletal muscle atonia during REM sleep with prominent motor
      activity accompanying dreaming.
    explanation: >-
      Links the released motor activity specifically to dreaming, which is what
      distinguishes this node from a generic nocturnal motor phenomenon.
  downstream:
  - target: Sleep-Related Injury
    description: >-
      Violent enacted behaviour causes injury to the patient and bed partner.
    causal_link_type: DIRECT
  - target: Progression to Overt Synucleinopathy
    description: >-
      Where the trigger is degenerative, the same alpha-synuclein pathology
      spreads beyond the brainstem to nigral and cortical structures. This edge
      does not apply to the antidepressant-associated or purely lesional forms.
    causal_link_type: INDIRECT_KNOWN_INTERMEDIATES

- name: Sleep-Related Injury
  description: >-
    The immediate consequence, and the one management addresses: bruising,
    lacerations, fractures, subdural haematoma, and injury to the bed partner.
    Environmental safety measures - removing bedside weapons and hard objects,
    padding, sleeping separately in severe uncontrolled cases - are graded as a
    good-practice statement necessary for appropriate management, ahead of any
    drug recommendation, which is an unusual ordering and reflects that the
    modifiable risk here is mechanical rather than pharmacological.
  role: consequence
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:36515157
    reference_title: "Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      It is critically important to help patients maintain a safe sleeping
      environment to prevent potentially injurious nocturnal behaviors.
    explanation: >-
      The guideline's good-practice statement, which establishes injury
      prevention as the primary management objective at this node.

- name: Progression to Overt Synucleinopathy
  description: >-
    The second consequence, of a different kind and applying only to the
    degenerative route. The brainstem pathology spreads to involve nigral and
    limbic-cortical structures, and the patient converts to Parkinson disease,
    dementia with Lewy bodies, or multiple system atrophy. Conversion runs at
    about 6.3% per year, reaching 73.5% by twelve years - high, but neither
    immediate nor universal, and the distinction matters when counselling. The
    post-mortem series adds a topographic dimension worth preserving: those who
    remained free of another neurological disorder, or who developed Parkinson
    disease without dementia, had alpha-synuclein largely confined to brainstem
    and limbic system with few coexisting pathologies, whereas those who
    developed dementia had diffuse cortical involvement and frequent comorbid
    Alzheimer pathology - so the destination, not just the timing, tracks the
    extent of spread.
  role: consequence
  biological_scale: ORGANISM
  evidence:
  - reference: PMID:30789229
    reference_title: "Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The overall conversion rate from iRBD to an overt neurodegenerative
      syndrome was 6.3% per year, with 73.5% converting after 12-year follow-up.
    explanation: >-
      Quantifies the conversion risk in a 1280-patient multicentre cohort, which
      is what allows this node to state a rate rather than an association.
  - reference: PMID:39577924
    reference_title: "Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      In individuals with IRBD without any other neurological disorder and in
      those who developed Parkinson's disease without dementia, α-synuclein was
      found in the brainstem and limbic system and rarely in the cortex, whereas
      coexisting proteinopathies were few and showed mild pathological burden.
    explanation: >-
      Supports the topographic claim in the node description - that the clinical
      destination tracks the anatomical extent of spread, not merely its
      duration.
  - reference: PMID:39577924
    reference_title: "Post-mortem neuropathology of idiopathic rapid eye movement sleep behaviour disorder: a case series."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Concomitant pathologies are frequent and their role remains to be
      clarified: some might have contributed to the development of dementia, but
      some might be age-related changes.
    explanation: >-
      Cited as PARTIAL because it withholds the causal reading of the comorbid
      pathologies rather than supporting it - the association with dementia is
      observed, its causal contribution explicitly not established.
phenotypes:
- category: Neurological
  name: Dream Enactment Behaviour
  description: >-
    Complex, often violent motor behaviour during REM sleep, matched to dream
    content, with alert waking and dream recall.
  phenotype_term:
    preferred_term: REM sleep behavior disorder
    term:
      id: HP:5200291
      label: REM sleep behavior disorder
    temporality: RECURRENT
  frequency: OBLIGATE
  evidence:
  - reference: PMID:30166532
    reference_title: REM sleep behaviour disorder.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      abnormal behaviours occurring during REM sleep, often as dream enactments
      that can cause injury
    explanation: >-
      OBLIGATE by definition rather than by observation: dream enactment history
      is a mandatory diagnostic criterion, so every diagnosed patient has it.
- category: Neurological
  name: REM Sleep Without Atonia
  description: >-
    Excess tonic or phasic submental (with or without limb) electromyographic
    activity during scored REM sleep on video polysomnography.
  phenotype_term:
    preferred_term: Abnormal rapid eye movement sleep
    term:
      id: HP:0002494
      label: Abnormal rapid eye movement sleep
  frequency: OBLIGATE
  evidence:
  - reference: PMID:30166532
    reference_title: REM sleep behaviour disorder.
    supports: SUPPORT
    evidence_source: OTHER
    snippet: >-
      characterized by loss of muscle atonia during REM sleep (known as REM sleep
      without atonia, or RSWA)
    explanation: >-
      OBLIGATE by definition: polysomnographic REM sleep without atonia is a
      mandatory criterion for definite diagnosis.
- category: Neurological
  name: Sleep-Related Injury
  description: >-
    Injury to the patient or bed partner resulting from enacted behaviour;
    lacerations, bruising, fractures and falls from bed.
  phenotype_term:
    preferred_term: Abnormal movement during sleep
    term:
      id: HP:5200300
      label: Abnormal movement during sleep
  evidence:
  - reference: PMID:36515157
    reference_title: "Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      the removal of bedside weapons, or objects that could inflict injury if
      thrown or wielded against a bed partner, is of paramount importance
    explanation: >-
      Supports injury as a recognised and management-relevant consequence; no
      frequency band is asserted, since the guideline does not quantify it.
diagnosis:
- name: Video polysomnography with quantified REM atonia scoring
  description: >-
    The mandatory diagnostic test, and the only one that establishes the entity.
    Submental (with or without limb) electromyographic activity is scored during
    REM sleep, and simultaneous video captures the behaviours. "Any" EMG activity
    at a threshold around 22% performs best against clinical diagnosis in
    population screening. Screening questionnaires are not adequate substitutes:
    a positive RBD screening questionnaire had good specificity but a positive
    predictive value under 8% in the general population, meaning over twelve in
    thirteen screen-positive people do not have the disorder.
  evidence:
  - reference: PMID:37816644
    reference_title: "REM Sleep Behavior Disorder and Its Possible Prodromes in General Population: Prevalence, Polysomnography Findings, and Associated Factors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Among the RWA parameters, any EMG activity showed the best association with
      the RBD and its possible prodromes (area under the curve, 0.917).
    explanation: >-
      Identifies the best-performing polysomnographic parameter for this
      diagnosis.
  - reference: PMID:37816644
    reference_title: "REM Sleep Behavior Disorder and Its Possible Prodromes in General Population: Prevalence, Polysomnography Findings, and Associated Factors."
    supports: REFUTE
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      RBDSQ score of ≥5 had good specificity but poor positive predictive value
      (PPV) for RBD (specificity 84.1% and PPV 7.7%)
    explanation: >-
      Cited as REFUTE against the use of questionnaire screening as a
      substitute for polysomnography at population level, which is the practical
      point this diagnostic entry makes.
treatments:
- name: Sleep Environment Safety Measures
  description: >-
    Removal of bedside weapons and injury-capable objects, padding of sharp
    furniture and headboard, soft floor covering beside the bed, and separate
    sleeping arrangements in severe uncontrolled cases. Graded as a good-practice
    statement whose implementation is necessary for appropriate management -
    that is, ahead of any pharmacological recommendation in the guideline's own
    ordering. It addresses the injury consequence directly and has no mechanistic
    action, which is precisely why it is the most reliably effective
    intervention available.
  therapeutic_modality: BEHAVIORAL
  treatment_term:
    preferred_term: Supportive Care
    term:
      id: NCIT:C15747
      label: Supportive Care
  target_mechanisms:
  - target: Sleep-Related Injury
    treatment_effect: INHIBITS
    description: >-
      Removes the physical means of injury without altering the released motor
      behaviour, acting on the consequence rather than on any upstream node.
  evidence:
  - reference: PMID:36515157
    reference_title: "Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The following good practice statement is based on expert consensus, and its
      implementation is necessary for the appropriate and effective management of
      patients with RBD
    explanation: >-
      Records both the recommendation and its evidence basis (expert consensus),
      and its placement ahead of the graded drug recommendations.
- name: Clonazepam
  description: >-
    Low-dose benzodiazepine that suppresses the enacted behaviours. It acts on
    the behavioural effector node and is not disease-modifying; the AASM
    recommendation is conditional. Sedation, falls and cognitive effects are
    material concerns in a population that is by definition in a
    neurodegenerative prodrome.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: clonazepam
      term:
        id: CHEBI:3756
        label: clonazepam
  target_mechanisms:
  - target: Dream Enactment Behaviour
    treatment_effect: INHIBITS
    description: >-
      Suppresses released motor behaviour without restoring REM atonia or
      altering the underlying pathology.
  evidence:
  - reference: PMID:36515157
    reference_title: "Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The AASM suggests that clinicians use clonazepam (vs no treatment) for the
      treatment of isolated RBD in adults. (CONDITIONAL).
    explanation: >-
      Cited as PARTIAL because the guideline's own strength assignment is
      conditional rather than strong.
- name: Immediate-Release Melatonin
  description: >-
    The alternative symptomatic agent, generally preferred where sedation, falls,
    or cognitive impairment make a benzodiazepine unattractive. Also a
    conditional recommendation, and also acting on the behavioural node rather
    than on the pathology.
  therapeutic_modality: SMALL_MOLECULE
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: melatonin
      term:
        id: CHEBI:16796
        label: melatonin
  target_mechanisms:
  - target: Dream Enactment Behaviour
    treatment_effect: INHIBITS
    description: >-
      Reduces frequency and intensity of enacted behaviours; not shown to restore
      REM atonia or to alter progression.
  evidence:
  - reference: PMID:36515157
    reference_title: "Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The AASM suggests that clinicians use immediate-release melatonin (vs no
      treatment) for the treatment of isolated RBD in adults. (CONDITIONAL).
    explanation: >-
      Cited as PARTIAL for the same reason as clonazepam: a conditional
      recommendation, so neither agent may be curated as established therapy.
prevalence:
- population: Korean population-based cohort aged 50-80, home polysomnography confirmed
  measure_type: POINT_PREVALENCE
  prevalence_class: ABOVE_1_IN_1000
  rate_per_100000: 1400.0
  rate_low: 1000.0
  rate_high: 1800.0
  notes: >-
    Polysomnography-confirmed prevalence in adults aged 50-80. Consistent with
    other recent population-based estimates of 1.18-1.34%. Isolated REM sleep
    without atonia, the presumed prodrome, was roughly nine times commoner at
    12.5%.
  evidence:
  - reference: PMID:37816644
    reference_title: "REM Sleep Behavior Disorder and Its Possible Prodromes in General Population: Prevalence, Polysomnography Findings, and Associated Factors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      Sex and DEB frequency-adjusted prevalence of RBD was 1.4% (95% CI
      1.0%-1.8%), isolated RWA was 12.5% (95% CI 11.3%-13.6%)
    explanation: >-
      Gives the adjusted point prevalence and confidence interval directly, and
      the prodromal-state figure quoted in the note.
  - reference: PMID:37816644
    reference_title: "REM Sleep Behavior Disorder and Its Possible Prodromes in General Population: Prevalence, Polysomnography Findings, and Associated Factors."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: >-
      The prevalence of polysomnography (PSG)–confirmed RBD is suggested at
      1.18%–1.34%, based on recent population-based studies.
    explanation: >-
      Corroborates the estimate against other population-based series, which is
      what the note refers to.
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
    evidence:
    - reference: PMID:30166532
      reference_title: REM sleep behaviour disorder.
      supports: SUPPORT
      evidence_source: OTHER
      snippet: >-
        Rapid eye movement (REM) sleep behaviour disorder (RBD) is a parasomnia
        that is characterized by loss of muscle atonia during REM sleep
      explanation: >-
        A parasomnia of brainstem origin, classified under the nervous-system
        chapter, the schema having no dedicated sleep chapter.
discussions:
- discussion_id: gap_neuroprotection_trial_window
  kind: KNOWLEDGE_GAP
  prompt: >-
    Can the decade-long prodromal window in this disorder be used to demonstrate
    neuroprotection, and what endpoint would show it?
  attaches_to:
  - pathophysiology#Progression to Overt Synucleinopathy
  rationale: >-
    This entry describes the most favourable setting neurodegeneration offers for
    a disease-modifying trial: an objectively verifiable marker, a defined
    at-risk population, a conversion rate high enough to power a trial (142-366
    patients per arm on published estimates), and roughly a decade of lead time
    before overt disease. Nothing has been shown to alter that trajectory, and
    the obstacle is partly an endpoint problem. Phenoconversion is a clinical
    diagnosis made years downstream and is a coarse, late outcome; the entry's
    own central node (quantified atonia loss) is closer to the pathology but its
    relationship to progression elsewhere in the brain is itself unresolved.
    Whether a shorter-term biological endpoint can substitute determines whether
    trials in this population are feasible at all.
  proposed_experiments:
  - experiment_id: exp_rbd_surrogate_endpoint_validation
    name: Validation of short-term progression markers against phenoconversion
    description: >-
      In an existing multicentre isolated-REM-sleep-behavior-disorder cohort with
      long follow-up, test candidate short-horizon markers - seed-amplification
      assay alpha-synuclein status, serial dopamine-transporter imaging,
      quantitative atonia loss, olfactory and autonomic measures - against
      observed phenoconversion, to establish whether any change over two to three
      years predicts the clinical endpoint well enough to serve as a trial
      outcome.
- discussion_id: gap_isolated_rwa_natural_history
  kind: KNOWLEDGE_GAP
  prompt: >-
    Does isolated REM sleep without atonia, nine times commoner than the full
    disorder, carry the same prodromal meaning?
  attaches_to:
  - pathophysiology#REM Sleep Without Atonia
  rationale: >-
    Population screening finds isolated REM sleep without atonia in 12.5% of
    adults aged 50-80, against 1.4% with the full disorder. If that finding
    carried the same phenoconversion risk, it would imply a prodromal
    synucleinopathy population an order of magnitude larger than currently
    recognised - which is either a major public-health observation or evidence
    that the polysomnographic marker is far less specific than its use as a
    mandatory criterion assumes. The entry curates the two as separable for that
    reason, and the question is directly answerable by follow-up rather than
    requiring new methods.
  proposed_experiments:
  - experiment_id: exp_isolated_rwa_prospective_followup
    name: Prospective follow-up of population-ascertained isolated atonia loss
    description: >-
      Long-term prospective surveillance of population-screened individuals with
      isolated REM sleep without atonia, isolated dream enactment, and neither,
      with incident parkinsonism and dementia as outcomes, to establish whether
      the polysomnographic marker alone confers the risk attached to the full
      syndrome.